Evidence map›Paper›PMID 37006993›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2023

Diagnostic accuracy of the NOVA Tuberculosis Total Antibody Rapid test for detection of pulmonary tuberculosis and infection with

Gideon Nsubuga, Samuel Kennedy, Yasha Rani, Zibran Hafiz, Soyeon Kim, Morten Ruhwald, David Alland, Jerrold Ellner, Moses Joloba, Susan E Dorman and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Quantum Dot-Based Nanosensors for In Vitro Detection ofNanomaterials (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Gideon NsubugaCollege of Health Sciences, Makerere University, Kampala, Uganda.
Samuel KennedyMedical University of South Carolina, Charleston, SC, USA.
Yasha RaniFrontier Science Foundation, Brookline, MA, USA.
Zibran HafizRutgers University - New Jersey Medical School, Newark, NJ, USA.
Soyeon KimFrontier Science Foundation, Brookline, MA, USA.
Morten RuhwaldFIND, Geneva, Switzerland.
David AllandRutgers University - New Jersey Medical School, Newark, NJ, USA.
Jerrold EllnerRutgers University - New Jersey Medical School, Newark, NJ, USA.
Moses JolobaCollege of Health Sciences, Makerere University, Kampala, Uganda.
Susan E DormanMedical University of South Carolina, Charleston, SC, USA.
Adam Penn-NicholsonFIND, Geneva, Switzerland.
Lydia NakiyingiCollege of Health Sciences, Makerere University, Kampala, Uganda.
Makerere University · UGRutgers New Jersey Medical SchoolFoundation for Innovative New Diagnostics · CHFrontier Science & Technology Research Foundation · USMedical University of South Carolina · US

Funding

FEND for TB supplement to accelerate BLINK X developmentU01AI152084 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, DORMAN, SUSAN E · 2020 to 2024
$20.0M
NIAID NIH HHS U01 AI152084
6 · The paper itself

Abstract

Background: The NOVA Tuberculosis Total Antibody Rapid Test is a commercially available lateral flow serological assay that is intended to be used as an aid in the diagnosis of tuberculosis. We conducted a study to estimate diagnostic accuracy of this assay for diagnosis of active pulmonary tuberculosis disease and for detection of Methods: This study used existing frozen plasma specimens that had been obtained previously from consenting HIV-negative adults in Cambodia, South Africa, and Vietnam whose tuberculosis status was rigorously characterized using sputum mycobacterial cultures and blood interferon gamma release assay. The investigational assay was performed in a single laboratory by laboratory staff specifically trained to conduct the assays according to the manufacturer's procedures. In addition, intensity of the test band was subjectively assessed. Results: Plasma specimens from 150 participants were tested. All testing attempts yielded a determinate result of either positive or negative. For diagnosis of active pulmonary tuberculosis disease, test sensitivity and specificity were 40.0 % (20/50, 95 % confidence interval [CI] 27.6 % to 53.8 %) and 85.0 % (95 % CI 76.7 % to 90.7 %), respectively. For detection of Conclusion: Study findings do not support a role for the NOVA Tuberculosis Test in current tuberculosis diagnostic algorithms.

Indexed as

Diagnostic accuracyLateral flowMycobacteriaSensitivitySpecificityTuberculosis

Identifiers

PMID37006993
PMCPMC10064436
OpenAlexW4328053525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.